Therapeutic effect of Shenfu Yixin granule on patients with chronic congestive heart failure combined with pulmonary hypertension

doi:10.3877/cma.j.issn.2095-6568.2018.02.004

Abstract

Abstract:

Objective

To observe the therapeutic effect of Shenfu Yixin granule in the treatment of patients with chronic congestive heart failure (CHF) combined with pulmonary hypertension (PH).

Methods

A total of 62 patients with CHF combined with PH admitted to Henan People's Hospital from January 2016 to December 2017 were selected and randomly divided into control group and experiment group, 31 cases in each group. The control group was treated with conventional Western medicine, and the experimental group was treated with Shenfu Yixin granule for one month. Pulmonary artery systolic pressure (PASP), left ventricular ejection fraction (LVEF) and stroke volume (SV) were compared between the two groups before and after treatment.

Results

After treatment, the level of PASP in the two groups decreased compared with that before treatment, and the level of PASP in experimental group was lower than that in control group (P<0.05). After treatment, the levels of SV and LVEF in the two groups were higher than those before treatment, and the levels of SV and LVEF in experimental group was higher than that in control group (P<0.05).

Conclusion

Shenfu Yixin granule can reduce PASP and improve cardiac function in patients with CHF combined with PH.

Key words: Chronic congestive heart failure, Pulmonary hypertension, Shenfu Yixin granule

Jiangtao Cheng. Therapeutic effect of Shenfu Yixin granule on patients with chronic congestive heart failure combined with pulmonary hypertension[J]. Chinese Journal of Heart and Heart Rhythm(Electronic Edition), 2018, 06(02): 74-76.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxzyxldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-6568.2018.02.004

https://zhxzyxldzzz.cma-cmc.com.cn/EN/Y2018/V06/I02/74

组别	例数	治疗前	治疗后	t值	P值
对照组	31	54.46±7.77	44.88±5.12	5.732	0.000
实验组	31	53.59±6.61	39.02±6.78	8.567	0.000
t值	?	0.474	3.840	?	?
P值	?	0.636	0.000	?	?

组别	例数	治疗前	治疗后	t值	P值
对照组	31	54.46±7.77	44.88±5.12	5.732	0.000
实验组	31	53.59±6.61	39.02±6.78	8.567	0.000
t值	?	0.474	3.840	?	?
P值	?	0.636	0.000	?	?

组别	例数	SV(ml)		LVEF(%)
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	31	50.33±9.07	57.42±8.23	38.61±5.42	41.05±5.85
实验组	31	51.05±10.24	69.36±10.54	38.67±5.33	51.29±6.72
t值	?	0.293	4.971	0.043	6.399
P值	?	0.770	0.000	0.965	0.000

组别	例数	SV(ml)		LVEF(%)
组别	例数	治疗前	治疗后	治疗前	治疗后
对照组	31	50.33±9.07	57.42±8.23	38.61±5.42	41.05±5.85
实验组	31	51.05±10.24	69.36±10.54	38.67±5.33	51.29±6.72
t值	?	0.293	4.971	0.043	6.399
P值	?	0.770	0.000	0.965	0.000

[1]	李骞，叶伟祥，张强，等. 西地那非治疗老年慢性心力衰竭并发肺动脉高压的效果[J]. 心脏杂志，2018, 30(2): 185-188.
[2]	国家中医药管理局. 中医病证诊断疗效标准[M]. 北京：中国医药科技出版社，2012: 3-4.
[3]	张妙林，章慧慧，袁红，等. 心脏超声预判慢性左心疾病相关性肺动脉高压患者临床疗效及近期预后[J]. 中国心血管杂志，2016, 21(5): 384-387.
[4]	诸葛瑞琪，倪新海. 左心疾病相关性肺动脉高压和药物治疗进展[J]. 中国心血管杂志，2016, 21(2): 165-170.
[5]	谢世阳，王幼平，王小晓，等. 参附益心颗粒对心力衰竭大鼠心肌ATP含量及解偶联蛋白－2的影响[J]. 中华中医药杂志，2017, 32(10): 4412-4415.

Please choose a citation manager

Content to export